RXR signaling targeted cancer therapy

) and truncated RXRα (tRXRα). Meanwhile, RXR-modulating drugs began to attract more interest from oncologists because of their potential in interfering with cancer cell proliferation, differentiation, and apoptosis according to the important and comprehensive regulation effects of RXR in tumorigenesis. Herein, we will review the comprehensive role of RXR between RXR signaling and oncogenesis, with a highlighted focus on the undervalued rexinoid-related cancer therapy, and discuss and propose its great potential in future clinics.

[1]  D. Sahoo,et al.  Inverse agonists of RAR/RXR signaling as lineage-specific anti-tumor agents against human Adenoid Cystic Carcinoma. , 2023, Journal of the National Cancer Institute.

[2]  Geoffrey Brown.  Targeting the Retinoic Acid Pathway to Eradicate Cancer Stem Cells , 2023, International journal of molecular sciences.

[3]  Mengxuan Zhu,et al.  The STAT family: key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment. , 2022, Seminars in cancer biology.

[4]  Xiaokun Zhang,et al.  Design, synthesis and biological evaluation of acyl hydrazones-based derivatives as RXRα-targeted anti-mitotic agents. , 2022, Bioorganic chemistry.

[5]  Keesook Lee,et al.  TR3 Enhances AR Variant Production and Transactivation, Promoting Androgen Independence of Prostate Cancer Cells , 2022, Cancers.

[6]  B. Niu,et al.  Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway , 2021, Journal of experimental & clinical cancer research : CR.

[7]  Jialin Li,et al.  α-Mangostin Induces Apoptosis and Inhibits Metastasis of Breast Cancer Cells via Regulating RXRα-AKT Signaling Pathway , 2021, Frontiers in Pharmacology.

[8]  E. Yang,et al.  The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer , 2021, Cancers.

[9]  D. Lambrechts,et al.  Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. , 2021, Cancer cell.

[10]  Geoffrey Brown,et al.  The RARγ Oncogene: An Achilles Heel for Some Cancers , 2021, International journal of molecular sciences.

[11]  T. Daemen,et al.  Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs , 2021, Oncoimmunology.

[12]  E. Ellsworth,et al.  The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer , 2020, Scientific Reports.

[13]  Z. Yin,et al.  Centrosomal Localization of RXRα Promotes PLK1 Activation and Mitotic Progression and Constitutes a Tumor Vulnerability. , 2020, Developmental cell.

[14]  A. Musacchio,et al.  BUB1 and CENP-U, Primed by CDK1, Are the Main PLK1 Kinetochore Receptors in Mitosis , 2020, Molecular cell.

[15]  Chunfu Wu,et al.  Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer , 2020, Molecular Cancer.

[16]  Joy J. Chen,et al.  Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer , 2020, bioRxiv.

[17]  K. Shah,et al.  TRAIL of Hope Meeting Resistance in Cancer. , 2020, Trends in cancer.

[18]  Ji Hyeon Kim,et al.  Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. , 2020, Chemical Society reviews.

[19]  L. Brunsveld,et al.  Nuclear receptor crosstalk — defining the mechanisms for therapeutic innovation , 2020, Nature Reviews Endocrinology.

[20]  Y. Shih,et al.  Upregulation of amphiregulin by retinoic acid and Wnt signalling promotes liver cancer cell proliferation , 2020, Journal of cellular physiology.

[21]  Jing Liu,et al.  Role of HDACs in normal and malignant hematopoiesis , 2020, Molecular Cancer.

[22]  W. Bourguet,et al.  Regulation of RXR-RAR Heterodimers by RXR- and RAR-Specific Ligands and Their Combinations , 2019, Cells.

[23]  I. Ellis,et al.  Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer , 2019, British Journal of Cancer.

[24]  E. Beierle,et al.  UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts , 2019, Translational oncology.

[25]  A. Viola,et al.  The Metabolic Signature of Macrophage Responses , 2019, Front. Immunol..

[26]  M. Conda-Sheridan,et al.  A review of the molecular design and biological activities of RXR agonists , 2019, Medicinal research reviews.

[27]  D. V. Von Hoff,et al.  Triptolide and Its Derivatives as Cancer Therapies. , 2019, Trends in pharmacological sciences.

[28]  Hua‐Lang Wu,et al.  Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling , 2019, Nature Communications.

[29]  Ke Wang,et al.  The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway , 2019, Cell Death & Disease.

[30]  E. Chan,et al.  Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. , 2018, Seminars in cancer biology.

[31]  S. Skvortsov,et al.  Therapy resistance mediated by cancer stem cells. , 2018, Seminars in cancer biology.

[32]  Xiaochi Ma,et al.  Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway , 2018, Journal of experimental & clinical cancer research : CR.

[33]  Zena Werb,et al.  Roles of the immune system in cancer: from tumor initiation to metastatic progression , 2018, Genes & development.

[34]  K. Flaherty,et al.  Toward Minimal Residual Disease-Directed Therapy in Melanoma , 2018, Cell.

[35]  Linyan Zhu,et al.  Overview of the structure-based non-genomic effects of the nuclear receptor RXRα , 2018, Cellular & Molecular Biology Letters.

[36]  Hien Dang,et al.  Single‐cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma , 2018, Hepatology.

[37]  H. Kakuta,et al.  Retinoid X Receptor Antagonists , 2018, International journal of molecular sciences.

[38]  G. Hu,et al.  RXRα provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells , 2018, Cell Death & Disease.

[39]  Ning Wang,et al.  Inhibition of cancer stem cell like cells by a synthetic retinoid , 2018, Nature Communications.

[40]  R. Liddington,et al.  Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα , 2017, Nature Communications.

[41]  Xiaomei Yan,et al.  TRC4, an improved triptolide derivative, specifically targets to truncated form of retinoid X receptor‐alpha in cancer cells , 2017, Biochemical pharmacology.

[42]  Chih-Yang Wang,et al.  Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells , 2015, Nature.

[43]  Guanghui Wang,et al.  NSC-640358 acts as RXRα ligand to promote TNFα-mediated apoptosis of cancer cell , 2015, Protein & Cell.

[44]  F. Lo‐Coco,et al.  Retinoic acid receptors: from molecular mechanisms to cancer therapy. , 2015, Molecular aspects of medicine.

[45]  J. Walter,et al.  The Cep192-organized aurora A-Plk1 cascade is essential for centrosome cycle and bipolar spindle assembly. , 2014, Molecular cell.

[46]  N. Sun,et al.  HtrA1 Downregulation Induces Cisplatin Resistance in Lung Adenocarcinoma by Promoting Cancer Stem Cell‐Like Properties , 2014, Journal of cellular biochemistry.

[47]  R. Evans,et al.  Nuclear Receptors, RXR, and the Big Bang , 2014, Cell.

[48]  S. Tavazoie,et al.  Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation , 2014, Cell.

[49]  Andrew J. Wilson,et al.  TR3 modulates platinum resistance in ovarian cancer. , 2013, Cancer research.

[50]  J. Quan,et al.  Structural basis for the inhibition of Polo-like kinase 1 , 2013, Nature Structural &Molecular Biology.

[51]  M. Vacca,et al.  Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. , 2013, Gastroenterology.

[52]  P. Tontonoz,et al.  Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR , 2012, Nature Reviews Molecular Cell Biology.

[53]  Zhijian J. Chen,et al.  Ubiquitination in signaling to and activation of IKK , 2012, Immunological reviews.

[54]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[55]  Y. Wan,et al.  Retinoid pathway and cancer therapeutics. , 2010, Advanced drug delivery reviews.

[56]  Yu Cao,et al.  NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. , 2010, Cancer cell.

[57]  L. D. De Luca,et al.  Therapeutic potential of "rexinoids" in cancer prevention and treatment. , 2009, Cancer research.

[58]  M. Shimizu,et al.  Strategy and mechanism for the prevention of hepatocellular carcinoma: Phosphorylated retinoid X receptor α is a critical target for hepatocellular carcinoma chemoprevention , 2009, Cancer science.

[59]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[60]  L. Altucci,et al.  RAR and RXR modulation in cancer and metabolic disease , 2007, Nature Reviews Drug Discovery.

[61]  R. Nasr,et al.  RXR is an essential component of the oncogenic PML/RARA complex in vivo. , 2007, Cancer cell.

[62]  Gregor Eichele,et al.  International Union of Pharmacology. LXIII. Retinoid X Receptors , 2006, Pharmacological Reviews.

[63]  Haralampos J. Milionis,et al.  Cutaneous T-cell lymphoma. , 2005, The Journal of dermatologic surgery and oncology.

[64]  M. Linton,et al.  Conditional Knockout of Macrophage PPARγ Increases Atherosclerosis in C57BL/6 and Low-Density Lipoprotein Receptor–Deficient Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[65]  H. Cottam,et al.  The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Ikura,et al.  The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. , 2005, Trends in biochemical sciences.

[67]  D. Crowe,et al.  A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands , 2004, Breast Cancer Research.

[68]  D. Agus,et al.  Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. , 2004, Cancer cell.

[69]  Lucia Altucci,et al.  The promise of retinoids to fight against cancer , 2001, Nature Reviews Cancer.

[70]  A. Itai,et al.  Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. , 2001, The Journal of clinical investigation.

[71]  L. Dardashti,et al.  Activation of specific RXR heterodimers by an antagonist of RXR homodimers , 1996, Nature.

[72]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[73]  R. Vessella,et al.  Inhibition of tumorigenic potential and prostate‐specific antigen expression in LNCaP human prostate cancer cell line by 13‐cis‐retinoic acid , 1994, International journal of cancer.

[74]  X. Yao,et al.  Targeting truncated retinoid X receptor-α by CF31 induces TNF-α-dependent apoptosis. , 2013, Cancer research.

[75]  Xìao-chun Xu.  Tumor-suppressive activity of retinoic acid receptor-beta in cancer. , 2007, Cancer letters.

[76]  I. Weinstein,et al.  Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management. , 2007, Gut.